Form 4 for CRDF Cardiff Oncology, Inc.

Accepted 2026-07-16 16:01:04 ET · period of report 2026-07-14 · accession 0001193125-26-306072 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-07-16 16:01	2026-07-14	CRDF	Mohindru Mani	CEO, Dir	P - Purchase	$1.46	+34.4K	59.1K	+139%	+$50.0K
D	2026-07-16 16:01	2026-07-14	CRDF	Mohindru Mani	CEO, Dir	P - Purchase	$0.00	+34.4K	34.4K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-07-14	P	A	34,364	$1.46	59,067	D	—	—
2	Derivative	Common Stock Purchase Warrant	2026-07-14	P	A	34,364	$0.00	34,364	D	$1.33 · — to —	34,364 Common Stock	(F1) Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders. (F2) The term of exercise is equal to five and one-half years after the Initial Exercise Date.